QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

NeurAxis Stock Price, News & Analysis (NASDAQ:NRXS)

$3.26
+0.26 (+8.67%)
(As of 11/29/2023 ET)
Compare
Today's Range
$2.25
$3.36
50-Day Range
$1.90
$4.18
52-Week Range
$1.80
$6.93
Volume
49,470 shs
Average Volume
40,835 shs
Market Capitalization
$17.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NRXS stock logo

About NeurAxis Stock (NASDAQ:NRXS)

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

NRXS Stock Price History

NRXS Stock News Headlines

NeurAxis reports Q3 results
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
NeurAxis Reports Third Quarter 2023 Financial Results
NeurAxis Announces CareFirst BCBS Policy Coverage
NeurAxis Secures $3 Million Financing
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Neuraxis Inc NRXS Stock Quote
NeurAxis Reports Second Quarter 2023 Financial Results
NeurAxis Announces Over $8 Million in IB-Stim™ Revenue
NeurAxis Highlights Strength of its Board of Directors
See More Headlines
Receive NRXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/21/2023
Today
11/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NRXS
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.68 million

Miscellaneous

Free Float
N/A
Market Cap
$15.87 million
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Brian Carrico (Age 41)
    President, CEO & Director
    Comp: $373.58k
  • Dr. Adrian Miranda (Age 53)
    Chief Medical Officer, Senior VP of Science & Technology and Director
    Comp: $266.35k
  • Mr. Thomas Carrico (Age 66)
    Chief Regulatory Officer & Director
    Comp: $287.2k
  • Mr. Christopher Robin Brown D.D.S. (Age 69)
    Founder, Director of Innovation & Director
  • Mr. Gary Peterson (Age 57)
    Founder, Director of Design & Engineering and Director
  • Mr. John G. Seale CPA (Age 63)
    CFO & Teasurer
  • Mr. Dan Clarence (Age 63)
    COO & Director














NRXS Stock Analysis - Frequently Asked Questions

Should I buy or sell NeurAxis stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeurAxis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NRXS shares.
View NRXS analyst ratings
or view top-rated stocks.

How have NRXS shares performed in 2023?

NeurAxis' stock was trading at $6.00 at the beginning of 2023. Since then, NRXS stock has decreased by 45.7% and is now trading at $3.26.
View the best growth stocks for 2023 here
.

How were NeurAxis' earnings last quarter?

NeurAxis, Inc. (NASDAQ:NRXS) issued its earnings results on Thursday, September, 21st. The company reported ($1.21) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.99. The business had revenue of $0.65 million for the quarter.

When did NeurAxis IPO?

(NRXS) raised $7 million in an initial public offering on Wednesday, August 9th 2023. The company issued 1,098,667 shares at a price of $6.00 per share.

Who are NeurAxis' major shareholders?

NeurAxis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (0.52%).

How do I buy shares of NeurAxis?

Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NRXS) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -